| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.001 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0009 | 1 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.005 | 1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.00087 | 1 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.00086 | 1 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.00076 | 1 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.00065 | 1 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.0009 | 1 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.00075 | 1 |